Sign In
13 Nov 2015 11:47
Ap24
FORM 38.5(a)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader | J.P. Morgan Securities plc |
Company dealt in | Pfizer Inc |
Class of relevant security to which the dealings being disclosed relate (Note 1) | Common Stock |
Date of dealing | 12 November 2015 |
2. DEALINGS (Note 2)
(a) Purchases and sales
Total number of relevant secuities acquired | Highest price paid (EUR)(Note 3) | Lowest price paid (EUR) (Note 3) |
198 | 31.2850 | 31.2850 |
Total number of securities disposed | Highest price received (USD) (Note 3) | Lowest price received (USD) (Note 3) |
2,136 | 33.5200
| 33.4600 |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 4) | Number of relevant securities (Note 5) | Price per unit (Note 3) |
Equity Swap | Short | 198 | 31.2880 |
Ap25
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 5) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 3) |
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 3) |
3. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securitiesunder any option referred to on this form or relating to the voting rights or future acquisitionor disposal of any relevant securities to which any derivative referred to on this form is referenced.If none, this should be stated.
Date of disclosure | 13 November 2015 |
Contact name | Tung Le
|
Telephone number | 020 7742 7272 |
Name of offeree/offeror with which connected | Allergan Plc |
Nature of connection (Note 6) | Adviser to Allergan Plc |
Follow the stocks
